Eosinophilic Gastroenteritis Treatment Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Epidemiology, Medication, and Companies by DelveInsight

Eosinophilic Gastroenteritis Companies are Allakos, AstraZeneca, Invea Therapeutics, Pfizer, Ception Therapeutics, Regeneron, EsoCap AG, Celgene, Allakos Inc., Ellodi Pharma, Takeda, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Novartis, EMS, Celgene, Oxagen Ltd, and others
(Albany, USA) DelveInsight's "Eosinophilic Gastroenteritis Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Eosinophilic Gastroenteritis, historical and forecasted epidemiology as well as the Eosinophilic Gastroenteritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Some of the key facts of the Eosinophilic Gastroenteritis Market Report:

* The Eosinophilic Gastroenteritis market size was valued approximately USD 78 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
* More than 31,000 cases of Eosinophilic Gastroenteritis were reported in the US in 2021, but only about 2,800 cases were reported in Spain
* In the United States in 2021, there were approximately 16,500 males and 15,000 females who had eosinophilic gastroenteritis. By 2032, the prevalence is anticipated to rise
* In 2021, Germany had the most common incidence of eosinophilic gastroenteritis among the EU5 nations (about 4,400 cases)
* Key Eosinophilic Gastroenteritis Companies: Allakos, AstraZeneca, Invea Therapeutics, Pfizer, Ception Therapeutics, Regeneron, EsoCap AG, Celgene, Allakos Inc., Ellodi Pharma, Takeda, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Novartis, EMS, Celgene, Oxagen Ltd, and others
* Key Eosinophilic Gastroenteritis Therapies: Lirentelimab, Benralizumab, INVA8001, Etrasimod, reslizumab, Dupilumab, ESO-101, CC-93538, AK002, APT-1011, budesonide, Mesalamine, IRL201104, QAX576, Florence 30 g/mL, RPC4046, OC000459, and others
* The Eosinophilic Gastroenteritis epidemiology based on gender analyzed that Eosinophilic Gastroenteritis shows slight predominance in males than females in the US. However, in eosinophilic esophagitis (EoE), there is no male predominance
* The Eosinophilic Gastroenteritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Eosinophilic Gastroenteritis pipeline products will significantly revolutionize the Eosinophilic Gastroenteritis market dynamics.
* In December 2024, Astrazeneca announced results of a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING).
* In October 2024, Regeneron Pharmaceuticals announced a Phase 2/3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis

To Know in detail about the Eosinophilic Gastroenteritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Eosinophilic Gastroenteritis Market Forecast [https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Eosinophilic Gastroenteritis Overview

Eosinophilic gastroenteritis (EGE) is a rare, chronic inflammatory condition characterized by an abnormal accumulation of eosinophils, a type of white blood cell, in the gastrointestinal (GI) tract. This disorder can affect any part of the GI tract, from the esophagus to the colon, and its symptoms vary depending on the location and depth of eosinophil infiltration. Common symptoms include abdominal pain, nausea, vomiting, diarrhea, weight loss, and in severe cases, intestinal obstruction or perforation. Eosinophilic Gastroenteritis is thought to result from an abnormal immune response, often associated with food allergies, environmental allergens, or other atopic conditions like asthma or eczema. The diagnosis of Eosinophilic Gastroenteritis typically involves a combination of clinical evaluation, endoscopic procedures, and biopsy, which reveal elevated eosinophil counts in the GI tissue.

Management of Eosinophilic Gastroenteritis primarily focuses on reducing inflammation and controlling symptoms. Dietary modifications, such as elimination diets to identify and avoid triggering foods, are often the first line of treatment. Pharmacological therapies include corticosteroids to reduce inflammation and immunomodulators to control the immune response. In some cases, biologic agents targeting specific pathways involved in eosinophil activation and recruitment may be used.

Despite its chronic nature, ongoing research into the pathophysiology of Eosinophilic Gastroenteritis and advancements in targeted therapies offer hope for improved management and outcomes for patients with this challenging condition.

Get a Free sample for the Eosinophilic Gastroenteritis Market Report: https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market [https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Eosinophilic Gastroenteritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Eosinophilic Gastroenteritis Epidemiology Segmentation:

The Eosinophilic Gastroenteritis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

* Total Prevalence of Eosinophilic Gastroenteritis
* Prevalent Cases of Eosinophilic Gastroenteritis by severity
* Gender-specific Prevalence of Eosinophilic Gastroenteritis
* Diagnosed Cases of Episodic and Chronic Eosinophilic Gastroenteritis

Download the report to understand which factors are driving Eosinophilic Gastroenteritis epidemiology trends @ Eosinophilic Gastroenteritis Epidemiology Forecast [https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Eosinophilic Gastroenteritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Eosinophilic Gastroenteritis market or expected to get launched during the study period. The analysis covers Eosinophilic Gastroenteritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Eosinophilic Gastroenteritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Eosinophilic Gastroenteritis Therapies and Key Companies

* Lirentelimab: Allakos
* Benralizumab: AstraZeneca
* INVA8001: Invea Therapeutics
* Etrasimod: Pfizer
* reslizumab: Ception Therapeutics
* Dupilumab: Regeneron
* ESO-101: EsoCap AG
* CC-93538: Celgene
* AK002: Allakos Inc.
* APT-1011: Ellodi Pharma
* budesonide: Takeda
* Mesalamine: Dr. Falk Pharma GmbH
* IRL201104: Revolo Biotherapeutics
* QAX576: Novartis
* Florence 30 g/mL: EMS
* RPC4046: Celgene
* OC000459: Oxagen Ltd

Discover more about therapies set to grab major Eosinophilic Gastroenteritis market share @ Eosinophilic Gastroenteritis Treatment Market [https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Eosinophilic Gastroenteritis Market Drivers

* Increasing disease burden due to increasing prevalence in the general population
* A better understanding of disease pathogenesis may lead to the identification of novel molecular targets for the treatment

Eosinophilic Gastroenteritis Market Barriers

* Lack of approved therapies indicated for EGE in the US, EU, and Japan
* Huge annual psychological, social, and economic burden (QALY), in advanced countries, due to EGE

Scope of the Eosinophilic Gastroenteritis Market Report

* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Eosinophilic Gastroenteritis Companies: Allakos, AstraZeneca, Invea Therapeutics, Pfizer, Ception Therapeutics, Regeneron, EsoCap AG, Celgene, Allakos Inc., Ellodi Pharma, Takeda, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Novartis, EMS, Celgene, Oxagen Ltd, and others
* Key Eosinophilic Gastroenteritis Therapies: Lirentelimab, Benralizumab, INVA8001, Etrasimod, reslizumab, Dupilumab, ESO-101, CC-93538, AK002, APT-1011, budesonide, Mesalamine, IRL201104, QAX576, Florence 30 g/mL, RPC4046, OC000459, and others
* Eosinophilic Gastroenteritis Therapeutic Assessment: Eosinophilic Gastroenteritis current marketed and Eosinophilic Gastroenteritis emerging therapies
* Eosinophilic Gastroenteritis Market Dynamics: Eosinophilic Gastroenteritis market drivers and Eosinophilic Gastroenteritis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Eosinophilic Gastroenteritis Unmet Needs, KOL's views, Analyst's views, Eosinophilic Gastroenteritis Market Access and Reimbursement

To know more about Eosinophilic Gastroenteritis companies working in the treatment market, visit @ Eosinophilic Gastroenteritis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Eosinophilic Gastroenteritis Market Report Introduction

2. Executive Summary for Eosinophilic Gastroenteritis

3. SWOT analysis of Eosinophilic Gastroenteritis

4. Eosinophilic Gastroenteritis Patient Share (%) Overview at a Glance

5. Eosinophilic Gastroenteritis Market Overview at a Glance

6. Eosinophilic Gastroenteritis Disease Background and Overview

7. Eosinophilic Gastroenteritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Eosinophilic Gastroenteritis

9. Eosinophilic Gastroenteritis Current Treatment and Medical Practices

10. Eosinophilic Gastroenteritis Unmet Needs

11. Eosinophilic Gastroenteritis Emerging Therapies

12. Eosinophilic Gastroenteritis Market Outlook

13. Country-Wise Eosinophilic Gastroenteritis Market Analysis (2019-2032)

14. Eosinophilic Gastroenteritis Market Access and Reimbursement of Therapies

15. Eosinophilic Gastroenteritis Market Drivers

16. Eosinophilic Gastroenteritis Market Barriers

17. Eosinophilic Gastroenteritis Appendix

18. Eosinophilic Gastroenteritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=eosinophilic-gastroenteritis-treatment-market-2032-ema-pdma-fda-approvals-clinical-trials-therapies-epidemiology-medication-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting



This release was published on openPR.